A phase 2, multi-center, open-label study of the safety, tolerability and immunogenicity of Novartis meningococcal B vaccine when administered at a 0, 2, 6-month schedule and of a single dose of Novartis meningococcal ACWY vaccine in healthy at-risk adults 18-50 years of age.

Trial Profile

A phase 2, multi-center, open-label study of the safety, tolerability and immunogenicity of Novartis meningococcal B vaccine when administered at a 0, 2, 6-month schedule and of a single dose of Novartis meningococcal ACWY vaccine in healthy at-risk adults 18-50 years of age.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2016

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis; Novartis Vaccines
  • Most Recent Events

    • 16 Dec 2011 Company Novartis Vaccines added to the associations field as reported by ClinicalTrials.gov record.
    • 18 Nov 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 18 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top